#Truvada

Researchers believe that hepatitis C is spreading through sex from the HIV-positive population to those who don’t have HIV.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

One percent of gay and bi men in a Dutch PrEP study contracted hepatitis C annually; of those cured, one in four were reinfected per year.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Largest-ever analysis of bone loss in the HIV population found that treating hep C, taking vitamin D and exercising might be preventive.

In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.

Another initiative of the Elton John AIDS Foundation will focus on HIV and hep C in Eastern Europe and Central Asia.

The rebranding reflects expanded services, including a medical clinic and a focus on STIs and hepatitis.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Such generic drugs could save nations huge sums in the coming years.

Two cases suggest that Viread alone may not be enough to prevent HIV through pre-exposure prophylaxis (PrEP)

Two and a half years into a PrEP program in San Francisco, none of the more than 600 gay men taking Truvada have contracted the HIV.